SightfileU.S. market data from official filings

ROCKET PHARMACEUTICALS I (RCKT)

Name: ROCKET PHARMACEUTICALS I (RCKT) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001281895 · EDGAR filings · Updated 2026-07-14

ROCKET PHARMACEUTICALS I (RCKT) has reported institutional ownership of 89.0%, with 196 institutional managers holding positions valued at $347.8M per the latest 13F reporting period.

Institutional ownership

89.0%

Institutional managers

196

Reported 13F value

$347.8M

Insider activity

75 trans.

−$242.3K net selling

Latest updates

2026-07-14 — Employee-plan registration (S-8) filed
2026-07-08 — Initial insider ownership filed (Form 3)
2026-07-07 — Notice of proposed sale filed (Form 144)
2026-07-06 — Insider transaction reported (Form 4)
2026-07-06 — Insider transaction reported (Form 4)
2026-07-06 — Insider transaction reported (Form 4)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, ROCKET PHARMACEUTICALS I has 196 institutional holders and institutional ownership of 89.0%.

Insider activity

Insiders reported 75 transactions (4 buys, 36 sells) across 20 reporting insiders, with a net reported value of −$242.3K.

Related companies

FORTE BIOSCIENCES INC (FBRX) · ATAIBECKLEY (ATAI) · NEUROPACE INC (NPCE) · BENITEC BIOPHARMA INC (BNTC) · NEUROGENE INC (NGNE) · PRIME MEDICINE INC (PRME)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-14.